MA51899A - Inhibiteurs de btk et de leurs mutants - Google Patents

Inhibiteurs de btk et de leurs mutants

Info

Publication number
MA51899A
MA51899A MA051899A MA51899A MA51899A MA 51899 A MA51899 A MA 51899A MA 051899 A MA051899 A MA 051899A MA 51899 A MA51899 A MA 51899A MA 51899 A MA51899 A MA 51899A
Authority
MA
Morocco
Prior art keywords
btk
mutants
inhibitors
Prior art date
Application number
MA051899A
Other languages
English (en)
Inventor
Yi Chen
Original Assignee
Newave Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newave Pharmaceutical Inc filed Critical Newave Pharmaceutical Inc
Publication of MA51899A publication Critical patent/MA51899A/fr

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
    • G06Q20/349—Rechargeable cards
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
    • G06Q20/341—Active cards, i.e. cards including their own processing means, e.g. including an IC or chip

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Business, Economics & Management (AREA)
  • Strategic Management (AREA)
  • Accounting & Taxation (AREA)
  • Computer Hardware Design (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051899A 2018-02-19 2019-02-15 Inhibiteurs de btk et de leurs mutants MA51899A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862631945P 2018-02-19 2018-02-19

Publications (1)

Publication Number Publication Date
MA51899A true MA51899A (fr) 2020-12-30

Family

ID=65685969

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051899A MA51899A (fr) 2018-02-19 2019-02-15 Inhibiteurs de btk et de leurs mutants

Country Status (12)

Country Link
US (3) US11501284B2 (fr)
EP (1) EP3755702A1 (fr)
JP (1) JP7535949B2 (fr)
KR (1) KR102861971B1 (fr)
CN (2) CN111741959B (fr)
AU (1) AU2019222475B2 (fr)
CA (1) CA3088796A1 (fr)
IL (1) IL276575B2 (fr)
MA (1) MA51899A (fr)
MX (1) MX2020008627A (fr)
SG (1) SG11202006274XA (fr)
WO (1) WO2019161152A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111741959B (zh) * 2018-02-19 2023-09-05 广州麓鹏制药有限公司 Btk的抑制剂及其突变体
EP3930717A1 (fr) * 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibiteurs de btk et leurs mutants
WO2021038540A1 (fr) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk
WO2021066958A1 (fr) * 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibiteurs de btk et leurs mutants
JP7763767B2 (ja) 2020-02-20 2025-11-04 ハチメド リミテッド ヘテロアリール複素環式化合物およびその使用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
MX2023001865A (es) 2020-08-14 2023-05-09 Guangzhou Lupeng Pharmaceutical Company Ltd Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
KR20230104125A (ko) 2020-09-21 2023-07-07 허치슨 메디파르마 리미티드 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도
CA3202745A1 (fr) * 2020-12-20 2022-06-23 Yi Chen Degradeur de btk
CN117897388A (zh) * 2020-12-20 2024-04-16 广州麓鹏制药有限公司 Btk蛋白降解剂
CN115960124B (zh) * 2023-02-23 2025-02-18 康化(上海)新药研发有限公司 一种2-氟-3-甲酰基-吡啶-4-硼酸频哪醇酯的合成方法
IL326381A (en) 2023-08-07 2026-04-01 Guangzhou Lupeng Pharmaceutical Co Ltd Crystalline form VI of acrylamide compound and method for its preparation and use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
KR101862327B1 (ko) * 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2964642B1 (fr) 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibiteurs de la tyrosine kinase de bruton
EP3483167A1 (fr) 2013-06-26 2019-05-15 AbbVie Inc. Carboxamides primaires comme inhibiteurs de btk
JP2016535764A (ja) * 2013-10-04 2016-11-17 ビヨンド オンコロジー ファーマシューティカル エルエルシー ブルトンのチロシンキナーゼの阻害剤
US9260415B2 (en) * 2013-12-05 2016-02-16 Genentech, Inc. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2018109050A1 (fr) 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation d'inhibiteurs de btk
JP2021512059A (ja) 2018-01-29 2021-05-13 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用方法
CN111741959B (zh) * 2018-02-19 2023-09-05 广州麓鹏制药有限公司 Btk的抑制剂及其突变体
EP3930717A1 (fr) 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibiteurs de btk et leurs mutants
WO2021066958A1 (fr) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibiteurs de btk et leurs mutants
WO2021091575A1 (fr) 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de btk par l'intermédiaire de la voie de l'ubiquitine-protéosome

Also Published As

Publication number Publication date
WO2019161152A1 (fr) 2019-08-22
KR20200122348A (ko) 2020-10-27
US12086788B2 (en) 2024-09-10
JP7535949B2 (ja) 2024-08-19
KR102861971B1 (ko) 2025-09-19
CN111741959B (zh) 2023-09-05
IL276575B2 (en) 2024-05-01
EP3755702A1 (fr) 2020-12-30
IL276575A (en) 2020-09-30
AU2019222475B2 (en) 2024-08-15
SG11202006274XA (en) 2020-07-29
US20250045728A1 (en) 2025-02-06
AU2019222475A1 (en) 2020-07-30
IL276575B1 (en) 2024-01-01
CA3088796A1 (fr) 2019-08-22
US11501284B2 (en) 2022-11-15
JP2021514390A (ja) 2021-06-10
US20200377478A1 (en) 2020-12-03
CN111741959A (zh) 2020-10-02
MX2020008627A (es) 2020-09-21
CN117209502A (zh) 2023-12-12
US20230140433A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287223A (en) Kras g12c inhibitors and methods of using the same
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL287940A (en) Fgfr inhibitors and methods of use thereof
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL271025A (en) Multibiotic agents and methods of using the same
IL276575A (en) BTK inhibitors and their mutants
EP3768664A4 (fr) Inhibiteurs de shp2 et leurs utilisations
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
IL283106A (en) Erk inhibitors and uses thereof
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
DK3737765T4 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
EP3801500A4 (fr) Inhibiteurs de sarm1
IL281438A (en) Pyridazinones and methods of use thereof
EP3938369A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
HRP20251592T1 (hr) Inhibitori arginaze i metode njihove primjene
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
IL283782A (en) Anellosomes and methods of use